Assessing the effectiveness of Interleukin-2 therapy in experimental type 1 diabetes.

ABSTRACT:

Aim

Much focus of immunotherapy for type 1 diabetes (T1D) has been devoted on selectively boosting regulatory T (Treg) cells using low dose IL-2 due to their constitutive expression of IL-2Rα, CD25. However, several clinical trials using a low dose of IL-2 only showed a limited improvement of metabolic control. It can therefore be hypothesized that further decreasing IL-2 dosage may increase the selective responsiveness of Treg cells.

Methods

We induced experimental T1D using multiple low dose streptozotocin (STZ) injections and treated the mice with an ultra-low dose IL-2 (uIL-2, approximately 7-fold lower than low dose). Immune response was studied using multicolor flow cytometry.

Results

We found that uIL-2 did not protect STZ mice from developing hyperglycemia. It

SUBMITTER: Luo Z 

PROVIDER: S-EPMC11291609 | biostudies-literature | 2024 Feb

REPOSITORIES: biostudies-literature